糖皮质激素受体在泌尿系统恶性肿瘤中的研究进展  

Research progress of glucocorticoid receptor in urological malignant tumors

作　　者：周启东[1] 蒋光亮[1] 徐可[1] Zhou Qidong Jiang Guangliang Xu Ke(Department of Urology, Huashan Hospital Affiliated to Fudan University, Shanghai 200040, Chin)

机构地区：[1]复旦大学附属华山医院泌尿外科,上海200040

出　　处：《国际肿瘤学杂志》2017年第6期476-479,共4页Journal of International Oncology

基　　金：国家自然科学基金（81372756）

摘　　要：糖皮质激素受体（GR）是类固醇激素核受体超家族成员，可介导糖皮质激素等配体信号，调节靶基因转录，发挥生物学活性。GR在肾癌、膀胱癌和前列腺癌三大泌尿系统恶性肿瘤中均有不同程度表达，能影响肿瘤细胞代谢过程，并与肿瘤发生、发展和预后等环节密切相关。GR为泌尿系统恶性肿瘤的靶向治疗和内分泌治疗提供了重要思路。Glucocorticoid receptor （GR）, a member of the steroid receptor superfamily, can mediate the signal pathway of ligands like glucocortieoids, regulate the transcription of target genes, and exert biological activity. GR is expressed in different degrees in three major kinds of urological malignant tumors including renal cancer, bladder cancer and prostate cancer. It also affects the metabolism of tumor cells, and is closely related to the occurrence, development and prognosis of tumors. GR provides an important clue for targeted therapy and endocrine therapy of urological malignant tumors.

关 键 词：受体 糖皮质激素 肾肿瘤 膀胱肿瘤 前列腺肿瘤 

分 类 号：R737[医药卫生—肿瘤]